The distinction between these features of tau pathology in relation to cognition may allow for quicker clinical identification of preclinical AD cognitive symptoms, resulting in quicker pathological screening, diagnosis, and better-informed therapeutic routes for treatment. This evidence concerns the gene MAPT and Alzheimer disease.